Replies to post #415 on Aratana Therapeutics Inc (fka PETX)

[terry hallinan]

Blue, Biotech;

This is from a transcript of the earnings teleconference from St. Peter, PETX CEO:

Regarding our second quarter 2018 financial results, as reported in our earnings release issued last evening, our total net revenues for the second quarter ended June 30, 2018 were $4.9 million. This compares to $5.2 million in the second quarter of 2017 which as a reminder included $3.7 million in product sales of the GALLIPRANT finished goods to Elanco.

Nothing to go wild over but PETX's own sales look a smidgen better.

Best, Terry